Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160332743> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W2160332743 endingPage "223" @default.
- W2160332743 startingPage "219" @default.
- W2160332743 abstract "The efficacy and safety of the new prostaglandin E1 (PGE1) synthetic analogue, rioprostil, 300 micrograms b.d. and cimetidine, 400 mg b.d., on duodenal ulcer healing are compared in an international, multicentre, double-blind study. A total of 257 patients have entered the study; 243 are considered eligible for efficacy analysis and 207 for safety analysis. After 4 and 6 weeks of treatment, the endoscopic healing rates do not significantly differ between the two groups, being 55% and 83% respectively with rioprostil vs. 60% and 78% respectively with cimetidine. The major adverse effect attributable to rioprostil is diarrhoea, which was documented in 11% of patients compared with 1% of patients taking cimetidine. However, central nervous system complaints are twice as frequent in the cimetidine group. Monitoring of clinical laboratory tests show no significant abnormalities when compared with the baseline values during the administration of either drug. This study documents that rioprostil, at the dosage of 300 micrograms b.d., is as effective and safe as cimetidine in the short-term therapy of duodenal ulcer." @default.
- W2160332743 created "2016-06-24" @default.
- W2160332743 creator A5000127898 @default.
- W2160332743 creator A5001903135 @default.
- W2160332743 creator A5008537194 @default.
- W2160332743 creator A5010154384 @default.
- W2160332743 creator A5011545004 @default.
- W2160332743 creator A5022025305 @default.
- W2160332743 creator A5032795833 @default.
- W2160332743 creator A5041220396 @default.
- W2160332743 creator A5050761434 @default.
- W2160332743 creator A5062440484 @default.
- W2160332743 creator A5066851466 @default.
- W2160332743 creator A5068863854 @default.
- W2160332743 creator A5070496114 @default.
- W2160332743 date "1989-01-01" @default.
- W2160332743 modified "2023-09-26" @default.
- W2160332743 title "Rioprostil in the Short-Term Treatment of Duodenal Ulcer: A Multicentre Double-Blind Trialvs.Cimetidine" @default.
- W2160332743 cites W2038326072 @default.
- W2160332743 cites W2040556013 @default.
- W2160332743 cites W2052375832 @default.
- W2160332743 cites W2337936139 @default.
- W2160332743 doi "https://doi.org/10.3109/00365528909091217" @default.
- W2160332743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2510272" @default.
- W2160332743 hasPublicationYear "1989" @default.
- W2160332743 type Work @default.
- W2160332743 sameAs 2160332743 @default.
- W2160332743 citedByCount "0" @default.
- W2160332743 crossrefType "journal-article" @default.
- W2160332743 hasAuthorship W2160332743A5000127898 @default.
- W2160332743 hasAuthorship W2160332743A5001903135 @default.
- W2160332743 hasAuthorship W2160332743A5008537194 @default.
- W2160332743 hasAuthorship W2160332743A5010154384 @default.
- W2160332743 hasAuthorship W2160332743A5011545004 @default.
- W2160332743 hasAuthorship W2160332743A5022025305 @default.
- W2160332743 hasAuthorship W2160332743A5032795833 @default.
- W2160332743 hasAuthorship W2160332743A5041220396 @default.
- W2160332743 hasAuthorship W2160332743A5050761434 @default.
- W2160332743 hasAuthorship W2160332743A5062440484 @default.
- W2160332743 hasAuthorship W2160332743A5066851466 @default.
- W2160332743 hasAuthorship W2160332743A5068863854 @default.
- W2160332743 hasAuthorship W2160332743A5070496114 @default.
- W2160332743 hasConcept C126322002 @default.
- W2160332743 hasConcept C142724271 @default.
- W2160332743 hasConcept C197934379 @default.
- W2160332743 hasConcept C204787440 @default.
- W2160332743 hasConcept C27081682 @default.
- W2160332743 hasConcept C2778062832 @default.
- W2160332743 hasConcept C2779837120 @default.
- W2160332743 hasConcept C2780035454 @default.
- W2160332743 hasConcept C2780719153 @default.
- W2160332743 hasConcept C2991744798 @default.
- W2160332743 hasConcept C2993747882 @default.
- W2160332743 hasConcept C535046627 @default.
- W2160332743 hasConcept C71924100 @default.
- W2160332743 hasConcept C90924648 @default.
- W2160332743 hasConcept C98274493 @default.
- W2160332743 hasConceptScore W2160332743C126322002 @default.
- W2160332743 hasConceptScore W2160332743C142724271 @default.
- W2160332743 hasConceptScore W2160332743C197934379 @default.
- W2160332743 hasConceptScore W2160332743C204787440 @default.
- W2160332743 hasConceptScore W2160332743C27081682 @default.
- W2160332743 hasConceptScore W2160332743C2778062832 @default.
- W2160332743 hasConceptScore W2160332743C2779837120 @default.
- W2160332743 hasConceptScore W2160332743C2780035454 @default.
- W2160332743 hasConceptScore W2160332743C2780719153 @default.
- W2160332743 hasConceptScore W2160332743C2991744798 @default.
- W2160332743 hasConceptScore W2160332743C2993747882 @default.
- W2160332743 hasConceptScore W2160332743C535046627 @default.
- W2160332743 hasConceptScore W2160332743C71924100 @default.
- W2160332743 hasConceptScore W2160332743C90924648 @default.
- W2160332743 hasConceptScore W2160332743C98274493 @default.
- W2160332743 hasIssue "sup164" @default.
- W2160332743 hasLocation W21603327431 @default.
- W2160332743 hasLocation W21603327432 @default.
- W2160332743 hasOpenAccess W2160332743 @default.
- W2160332743 hasPrimaryLocation W21603327431 @default.
- W2160332743 hasRelatedWork W1970169386 @default.
- W2160332743 hasRelatedWork W2030809922 @default.
- W2160332743 hasRelatedWork W2080977223 @default.
- W2160332743 hasRelatedWork W2160332743 @default.
- W2160332743 hasRelatedWork W2412611270 @default.
- W2160332743 hasRelatedWork W2414684911 @default.
- W2160332743 hasRelatedWork W2415356883 @default.
- W2160332743 hasRelatedWork W2415839004 @default.
- W2160332743 hasRelatedWork W2468780431 @default.
- W2160332743 hasRelatedWork W3112601716 @default.
- W2160332743 hasVolume "24" @default.
- W2160332743 isParatext "false" @default.
- W2160332743 isRetracted "false" @default.
- W2160332743 magId "2160332743" @default.
- W2160332743 workType "article" @default.